منابع مشابه
Hematopoietic growth factors
Erythropoietin is a lineage-specific distal-acting factor that stimulates maturation of committed erythroid progenitors to become mature erythrocytes.3 Carbohydrates, rich in sialic acid, make up 30% to 40% of the 34,000-Da molecule and are essential for its secretion, stability in the circulation, and biologic activity. Many earlier-acting factors, including stem cell factor/kit ligand, interl...
متن کامل[Hematopoietic growth factors].
Haematopoietic growth factors are a family of genetically determined low molecular weight glycoproteins which regulate the proliferation and differentiation of haemopoietic cells through specific membrane receptors. GCSF and GMCSF reduce the morbidity from infections associated with the neutropenia induced by chemotherapy of onco-haematological neoplasia; EPQ totally corrects not only the anaem...
متن کاملHematopoietic growth factors in the elderly
Abbreviations: acute myeloid leukemia, (AML); American Society of Clinical Oncology, (ASCO); bone marrow, (BM); end stage renal disease, (ESRD); erythropoietin, (EPO); granulocyte colony-stimulating factor, (G-CSF); Granulocyte-macrophage colony-stimulating factor, (GM-CSF); hematopoietic growth factors, (HGFs); hematopoietic stem cell, (HSC); hemoglobin, (Hgb); idiopathic thrombocytopenic purp...
متن کاملHematopoietic growth factors and transfusion medicine.
At least 20 different hematopoietic drugs (see Table 1) are currently under investigation. These most likely will impact on all aspects of transfusion therapy. Which agents to use and in what combinations will be the subject of scrutiny for many years to come as scientists try to recreate and enhance the process of hematopoiesis. Perhaps someday blood cells and hematopoietic progenitor cells ca...
متن کاملHematopoietic growth factors in myelodysplastic syndromes.
Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Administration (FDA)-approved indication for any of the HGFs. Erythropoiesis-stim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Investigation
سال: 1987
ISSN: 0021-9738
DOI: 10.1172/jci112988